Anti-TNFR2 monoclonal antibody LBL-019 in patients with advanced malignant tumors: A phase I, first-in-human, open-label, multicenter, dose escalation Study.

被引：0
|
作者：
Zhou, Fei
Li, Wei
Chen, Yu
Lin, Jing
Chen, Ling
Zhang, Huishan
Dong, Xiaorong
Tong, Fan
Zhang, Ruiguang
Yin, Yongmei
Liang, Yan
Yang, Nong
Hu, Sheng
Zhuang, Wei
Li, Tao
Cai, Shengli
Zhou, Caicun
机构：
[1] Tongji Univ, Shanghai Pulm Hosp, Dept Med Oncol, Sch Med, Shanghai, Peoples R China
[2] Tongji Univ, Thorac Canc Inst, Sch Med, Shanghai, Peoples R China
[3] Fujian Canc Hosp, Dept Oncol, Fuzhou, Peoples R China
[4] Fujian Canc Hosp, Fuzhou, Peoples R China
[5] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Wuhan, Peoples R China
[6] Nanjing Med Univ, Dept Oncol, Affiliated Hosp 1, Nanjing, Peoples R China
[7] Hunan Canc Hosp, Lung Gastrointestinal & Oncol Dept, Changsha, Peoples R China
[8] Hubei Canc Hosp, Dept Internal Med Oncol, Wuhan, Peoples R China
[9] Nanjing Leads Biolabs Co Ltd, Nanjing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14580
引用
收藏
页数：1
相关论文
共 50 条
  • [11] A first-in-human, open-label, dose escalation and expansion study of orally administered NX-019 in patients with advanced EGFR mutant cancer.
    Spira, Alexander I.
    Kim, Dong-Wan
    Ahn, Myung-Ju
    Kim, Sang-We
    Hong, Min Hee
    Dusek, Rachel
    Gammon, Guy M.
    Wilson, Keith
    Yang, James Chih-Hsin
    Massarelli, Erminia
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [12] A First-in-Human, Phase I, Multicenter, Open-Label, Dose-Escalation Study of PCA062: An Antibody-Drug Conjugate Targeting P-Cadherin, in Patients With Solid Tumors
    Duca, Matteo
    Lim, Darren Wan-Teck
    Subbiah, Vivek
    Takahashi, Shunji
    Sarantopoulos, John
    Varga, Andrea
    D'Alessio, Joseph A.
    Abrams, Tinya
    Sheng, Qing
    Tan, Eugene Youchin
    Rosa, Maria Santos
    Gonzalez-Maffe, Juan
    Sand-Dejmek, Janna
    Fabre, Claire
    Martin, Miguel
    MOLECULAR CANCER THERAPEUTICS, 2022, 21 (04) : 625 - 634
  • [13] A phase I, first-in-human, multicenter, open-label, dose-escalation study of IPH5201 as monotherapy or in combination with durvalumab ± oleclumab in advanced solid tumours
    Powderly, J.
    Bendell, J. C.
    Carneiro, B. A.
    Italiano, A.
    Macarulla Mercade, T.
    Castanon Alvarez, E.
    Imbimbo, M.
    Massard, C.
    Mueller, N.
    Gasco-Hernandez, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S728 - S729
  • [14] Anti-LAG-3 antibody LBL-007 in combination with toripalimab in patients with unresectable or metastatic melanoma: A phase., open-label, multicenter, dose escalation/expansion study.
    Bai, Xue
    Li, Mei
    Pu, Xingxiang
    Cheng, Ying
    Chen, Jing
    Jiang, Yu
    Chen, Xue
    Liu, Jingjing
    Fan, Li
    Guo, Jun
    Si, Lu
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [15] AVZO-021-1001: A first-in-human open-label, multicenter phase I/II dose-escalation and expansion study evaluating AVZO-021 in adult patients with advanced solid tumors
    Dowlati, A.
    Richardson, D. L.
    Lorusso, P.
    Spira, A. I.
    Bashir, B.
    Hirmand, M.
    Mehta, M.
    Patel, M. R.
    ANNALS OF ONCOLOGY, 2024, 35 : S405 - S405
  • [16] Updated results from a phase I, open-label, multicenter, first-in-human study of AMG 404, a checkpoint inhibitor, in patients with advanced solid tumors
    Price, T. J.
    Prenen, H.
    Lugowska, I.
    Falchook, G. S.
    Monzon, J. G.
    Arkenau, H. T.
    Chawla, S. P.
    Hui, M. N.
    Kuboki, Y.
    Dziadziuszko, R.
    Ozawa, Y.
    Fernandez, M. E. Elez
    Lima, C. S. P. Rocha
    Subbiah, V.
    Tan, D. S. W.
    Wang, K.
    Hindoyan, A.
    Shi, W.
    Kistler, M.
    Sadraei, N. Hashemi
    ANNALS OF ONCOLOGY, 2021, 32 : S1440 - S1442
  • [17] A Phase I, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients with Advanced Gastrointestinal Stromal Tumor
    George, Suzanne
    Heinrich, Michael C.
    Somaiah, Neeta
    Oppelt, Peter
    McLeod, Robert
    Nishioka, Satoshi
    Kundu, Madan G.
    Qian, Xiaozhong
    Kumar, Prasanna
    Laadem, Abderrahmane
    Lau, Yvonne
    Tran, Brittany P.
    Fallon, Maura
    Dosunmu, Ololade
    Shi, Julia
    Naito, Yoichi
    CLINICAL CANCER RESEARCH, 2023, 29 (18) : 3659 - 3667
  • [18] First-in-human, phase 1, open-label, dose-escalation, dose-expansion study of ADCT901 as monotherapy in patients with select advanced solid tumors
    Harvey, R. Donald
    Falchook, Gerald Steven
    Naqash, Abdul Rafeh
    Kim, Joseph W.
    Dowlati, Afshin
    Le Bruchec, Yvan
    Coudert, Isabelle
    Ervin-Haynes, Annette L.
    Sommerhalder, David
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [19] A first-in-human, open-label, dose-escalation study of ERK1/2 inhibitor HMPL-295 in patients with advanced solid tumors
    Yu, X.
    Zhang, J.
    Liu, R.
    Deng, Y.
    Cai, Y.
    Sun, Y.
    Dang, Q.
    Hong, W.
    Song, Z.
    Guo, S.
    Gao, S.
    Su, W.
    Shi, M.
    Fan, S.
    Zhang, B.
    Pan, B.
    Ren, Y.
    Wang, J.
    Zhong, C.
    Ma, L.
    ANNALS OF ONCOLOGY, 2023, 34 : S1496 - S1497
  • [20] First-in-human phase I dose escalation study of MK-8033 in patients with advanced solid tumors
    Keedy, Vicki L.
    Lenz, Heinz-Josef
    Saltz, Leonard
    Whisenant, Jennifer G.
    Berlin, Jordan D.
    Camacho, Luis H.
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (05) : 860 - 868
12345